Contraline
PrivateLast Round
Series B
Jun 2, 2026
Est. Valuation
$53.5M
Total Funding Raised
$114.22M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Contraline is a biotechnology company developing a long-lasting, non-hormonal, and reversible male contraceptive hydrogel.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Contraline Comparables
Compare Contraline with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Next Life Sciences | 91% | |
| VasDeBlock medical ApS | 79% | |
| Population Council | 72% |
Contraline Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 2, 2026 | ||||
| Series A Extension | Nov 10, 2022 | ||||
| Series A | Oct 20, 2021 | ||||
| Grant | Nov 18, 2020 | ||||
| Grant | Jan 24, 2019 | ||||
Seed | Apr 18, 2017 |
Key People
Founding team and executive leadership
Contraline Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Male Contraceptive Initiative | Grant |
| RA Capital Management | Series B |
| GV | Series B, Series A Extension |
| Metaplanet Holdings | Series A, Series A Extension |
| Founders Fund | Series A, Seed |
| Invus Opportunities | Series B |
| Virginia Innovation Partnership Corporation | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2026
Grew 15% QoQ, from 26 to 30 employees.
- Jun 22, 2026
Grew 25% QoQ, from 24 to 30 employees.
Contraline Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Contraline's valuation, stock price, and market status.
Is Contraline a public or private company?
Contraline is a private company.
What is the current stock price of Contraline?
Contraline is a private company with no public stock price. No recent secondary market data is available.
How much is Contraline worth (valuation)?
Contraline's valuation is estimated at $53.5M based on funding round data.
Can I buy Contraline stock?
Contraline shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Contraline's last funding round?
Contraline's most recent funding round was Series B on November 10, 2022.
Who are the main investors in Contraline?
Key investors in Contraline include RA Capital Management, GV, Founders Fund, BVF Partners L.P., FundRx.
Will Contraline IPO soon?
No public IPO plans have been announced for Contraline.
How can I track Contraline secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Contraline's secondary market activity and sign up for updates.